Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $4.29B |
| Gross Profit (TTM) | $3.46B |
| EBITDA | $806.94M |
| Operating Margin | 23.00% |
| Return on Equity | 90.40% |
| Return on Assets | 10.10% |
| Revenue/Share (TTM) | $32.52 |
| Book Value | $8.06 |
| Price-to-Book | 34.56 |
| Price-to-Sales (TTM) | 8.98 |
| EV/Revenue | 8.27 |
| EV/EBITDA | 40.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 96.40% |
| Shares Outstanding | $133.51M |
| Float | $132.94M |
| % Insiders | 0.18% |
| % Institutions | 104.25% |
Volatility is currently expanding
Beyond analysts' top-and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with strong clinical data and $890 million in Q1 2026 revenue. ALNY's robust cash position ($3.0 billion) and GAAP profitability materially reduce investment risk and support pipeline development.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop.
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyon.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALNY and any ticker you trade — then tracks every position and per-strategy win rate.
